Aquios CL Flow Cytometer Wins Two International Business Awards
News Sep 22, 2015
Beckman Coulter Life Sciences has gained two prestigious business awards for its clinical flow cytometer, the Aquios CL Flow Cytometer- winning gold as Best New Product Feature of the Year for Pipeline Sample Processing and Silver in the Enterprise Product of the Year, both in the Best in Biz Awards 2015.
Dr. Mario Koksch, Vice President and General Manager of Beckman Coulter’s Cytometry Business Unit, commented: “The award is recognition of the drive for continuous innovation that is taking place in our Miami flow cytometry centre of excellence. The team of experts seek to find ways of supporting the clinical lab to help them make better use of lab resources, reduce operational costs and improve overall workflow.”
The small footprint ‘LOAD & GO’ instrument is already transforming the use of flow cytometry for routine applications such as immunophenotyping in the clinical laboratory. The instrument’s precision in establishing the lymphocyte gate makes it possible for labs to carry out high volume, T, B, and NK cell analysis instead of sending this out to an external lab. The instrument delivers first results within 20 minutes, with subsequent results at a rate of 25 samples per hour (for up to a full 96-well plate).
The Aquios CL Flow Cytometer was designed specifically for the modern Lean laboratory, which has to operate 24/7 and requires automated instruments to improve workflow, enhance quality and deliver a consistent turnaround time (TAT).
The Best in Biz is the only independent global business awards program judged by members of the press and industry analysts. More than 250 public and private companies representing all sectors of the global economy from more than 30 countries competed in Best in Biz Awards’ third annual International program.
Best in Biz Awards 2015 International honors were presented in a range of categories, including Fastest-Growing Company of the Year, Most Innovative Company of the Year, Support Department of the Year, Enterprise Product of the Year, Best New Version of the Year and Best New Product of the Year.
Patients in a new Northwestern Medicine study were able to comprehend words that were written but not said aloud. They could write the names of things they saw but not verbalize them. This provides an insight into the brain degeneration that defines the rare dementia termed primary progressive aphasia.